[go: up one dir, main page]

FR13C0029I2 - Compositions pour le traitement de troubles gastro-intestinaux - Google Patents

Compositions pour le traitement de troubles gastro-intestinaux

Info

Publication number
FR13C0029I2
FR13C0029I2 FR13C0029C FR13C0029C FR13C0029I2 FR 13C0029 I2 FR13C0029 I2 FR 13C0029I2 FR 13C0029 C FR13C0029 C FR 13C0029C FR 13C0029 C FR13C0029 C FR 13C0029C FR 13C0029 I2 FR13C0029 I2 FR 13C0029I2
Authority
FR
France
Prior art keywords
compositions
treatment
gastrointestinal disorders
gastrointestinal
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0029C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32854294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0029(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of FR13C0029I1 publication Critical patent/FR13C0029I1/fr
Application granted granted Critical
Publication of FR13C0029I2 publication Critical patent/FR13C0029I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
FR13C0029C 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastro-intestinaux Active FR13C0029I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44309803P 2003-01-28 2003-01-28
US47128803P 2003-05-15 2003-05-15
US51946003P 2003-11-12 2003-11-12
PCT/US2004/002390 WO2004069165A2 (fr) 2003-01-28 2004-01-28 Procedes et compositions pour le traitement de troubles gastro-intestinaux

Publications (2)

Publication Number Publication Date
FR13C0029I1 FR13C0029I1 (fr) 2013-07-05
FR13C0029I2 true FR13C0029I2 (fr) 2024-04-19

Family

ID=32854294

Family Applications (2)

Application Number Title Priority Date Filing Date
FR13C0029C Active FR13C0029I2 (fr) 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastro-intestinaux
FR13C0030C Active FR13C0030I1 (fr) 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastrointestinaux

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR13C0030C Active FR13C0030I1 (fr) 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastrointestinaux

Country Status (28)

Country Link
US (3) US20040266989A1 (fr)
EP (3) EP1911763B1 (fr)
JP (3) JP4584911B2 (fr)
KR (2) KR101227626B1 (fr)
CN (2) CN101787073B (fr)
AT (2) ATE365174T1 (fr)
AU (2) AU2004210161B2 (fr)
BE (1) BE2013C032I2 (fr)
BR (2) BRPI0407071B8 (fr)
CA (1) CA2514507C (fr)
CY (5) CY1110905T1 (fr)
DE (2) DE602004028678D1 (fr)
DK (3) DK1911763T3 (fr)
ES (3) ES2350123T3 (fr)
FR (2) FR13C0029I2 (fr)
HU (1) HUS1300022I1 (fr)
IL (2) IL169863A (fr)
LT (1) LTC1594517I2 (fr)
LU (2) LU92201I2 (fr)
MX (1) MXPA05008097A (fr)
NL (1) NL300593I2 (fr)
NO (3) NO334112B1 (fr)
NZ (2) NZ541595A (fr)
PT (3) PT1911763E (fr)
RU (2) RU2543350C2 (fr)
SG (2) SG168407A1 (fr)
SI (3) SI1594517T1 (fr)
WO (1) WO2004069165A2 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4206272B2 (ja) 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE365174T1 (de) * 2003-01-28 2007-07-15 Microbia Inc Zusammensetzungen zur behandlung von gastrointestinalen störungen
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
CA2529307C (fr) 2003-06-13 2013-12-24 Microbia, Inc. Methodes et compositions pour le traitement de troubles gastro-intestinaux
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
WO2005115412A2 (fr) * 2004-05-25 2005-12-08 University Of Georgia Research Foundation, Inc. Compositions et procedes de modulation d'une reponse immunitaire
EP1813271A4 (fr) * 2004-10-26 2008-05-21 Ajinomoto Kk Agent préventif/thérapeutique pour des douleurs viscérales
US20090253634A1 (en) * 2005-08-19 2009-10-08 Microbia, Inc. Methods and Compositions for the Treatment of Gastrointestinal Disorders
HUE044391T2 (hu) 2005-09-29 2019-10-28 Ipsen Pharma Készítmény gasztrointesztinális motilitászavar kezelésére
US20090305993A1 (en) * 2006-02-24 2009-12-10 Ironwood Pharmaceuticals, Inc. Methods and composition for the treatment of gastrointestinal disorders
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
EP2671584A3 (fr) * 2007-05-04 2014-03-26 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter des troubles associés à la rétention de sel ou de fluide
US8969514B2 (en) * 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
JP2011523662A (ja) 2008-06-04 2011-08-18 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110306125A1 (en) * 2008-06-30 2011-12-15 Ironwood Pharmaceuticals, Inc. Protein Expression Methods
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
NZ591713A (en) * 2008-08-15 2013-07-26 Ironwood Pharmaceuticals Inc Solid stable formulations of linaclotide for oral administration
WO2010059733A1 (fr) 2008-11-19 2010-05-27 Forest Laboratories Holdings Limited Forme cristalline de la linaclotide
WO2010065751A2 (fr) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations d'agonistes de guanylate cyclase c et méthode d'utilisation
ES2439998T3 (es) 2009-04-10 2014-01-27 Corden Pharma Colorado, Inc. Procedimiento para aislar linaclotida
MX2012001660A (es) * 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
EP2464373A1 (fr) 2009-08-13 2012-06-20 Ironwood Pharmaceuticals, Inc. Procédé de modulation de l'effet pharmacodynamique d'agonistes des récepteurs de guanylate cyclase administrés par voie orale
EP2499154B1 (fr) 2009-11-09 2016-12-21 Ironwood Pharmaceuticals, Inc. Traitements de troubles gastro-intestinaux
RU2012128509A (ru) * 2009-12-07 2014-01-20 Айронвуд Фармасьютикалз, Инк. Способы лечения заболеваний желудочно-кишечного тракта
WO2011103311A2 (fr) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Traitements de troubles gastro-intestinaux
WO2011145062A1 (fr) 2010-05-21 2011-11-24 Link Research & Grants Corporation Traitement des acouphènes et de dysfonctions auditives apparentées
EP2605786A4 (fr) * 2010-06-09 2014-03-12 Combimab Inc Peptides thérapeutiques
CA3040415A1 (fr) 2010-08-11 2012-02-16 Forest Laboratories Holdings Limited Formulations stables de linaclotide
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2011302006A1 (en) 2010-09-15 2013-03-07 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase C agonists and methods of use
US9303066B2 (en) 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012155101A1 (fr) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Traitements de troubles gastro-intestinaux
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MD480Z5 (ro) * 2011-07-07 2012-09-30 Эльвира АНДОН Metodă de tratament al colitei ulceroase nespecifice acute
CA2846230A1 (fr) 2011-08-17 2013-02-21 Ironwood Pharmaceuticals, Inc. Traitements pour des troubles gastro-intestinaux
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
US20140018307A1 (en) * 2012-07-12 2014-01-16 Forest Laboratories Holdings Ltd. Linaclotide compositions
RU2528641C2 (ru) * 2012-08-22 2014-09-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных с синдромом диспепсии в сочетании с избыточной массой тела
CN102875655B (zh) * 2012-09-29 2014-12-17 深圳翰宇药业股份有限公司 一种合成利那洛肽的方法
US20150361139A1 (en) 2013-01-30 2015-12-17 Sandoz Ag Crystalline form of linaclotide
WO2014151206A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
SI3288578T1 (sl) * 2015-05-01 2023-07-31 Ironwood Pharmaceuticals, Inc. Sestavki za čiščenje kolona in zdravljenje gastrointestinalnih motenj
WO2017160938A1 (fr) * 2016-03-15 2017-09-21 The Regents Of The University Of California Méthodes et compositions pour traiter et prévenir des maladies associées à l'intégrine α8β1
CN107929718A (zh) * 2017-10-19 2018-04-20 南京星银药业集团有限公司 Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法
EP3870263A4 (fr) * 2018-10-23 2022-08-03 ABK Biomedical Incorporated Dispositif d'administration
CN109467606A (zh) * 2018-11-15 2019-03-15 大连理工大学 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
RU2712761C1 (ru) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
CN111265653B (zh) * 2020-02-09 2023-05-09 华中科技大学同济医学院附属协和医院 心房利钠肽在制备炎症性肠病治疗药物中的应用
US20230035733A1 (en) * 2020-03-26 2023-02-02 Dusa Pharmaceuticals, Inc. Management of dermal neurofibromatosis lesions
WO2023144292A1 (fr) 2022-01-28 2023-08-03 Fresenius Kabi Ipsum S.R.L. Procédé de préparation de linaclotide
WO2025207484A1 (fr) * 2024-03-25 2025-10-02 Merveille.Ai Utilisation d'aprépitant et d'un dipeptide cyclique pour le contrôle du poids

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32684A (en) * 1861-07-02 Stump-extkactob
US152868A (en) * 1874-07-07 Improvement in type-setting machines
US121961A (en) * 1871-12-19 Improvement in devices for supporting pipe-cores
US73628A (en) * 1868-01-21 mitchell
US258687A (en) * 1882-05-30 Grain-binder
US266989A (en) * 1882-11-07 Automatic fire
US232013A (en) * 1880-09-07 Henry h
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
IT1217123B (it) 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (fr) 1989-07-28 1992-01-15 Debiopharm Sa
CA2046830C (fr) 1990-07-19 1999-12-14 Patrick P. Deluca Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (fr) 1991-04-02 1994-12-23 Logeais Labor Jacques Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5140102A (en) 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
AU689438B2 (en) 1991-12-30 1998-04-02 Azur Pharma International Limited Methods of producing analgesia and enhancing opiate analgesia
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
ATE236655T1 (de) 1993-01-06 2003-04-15 Kinerton Ltd Ionische molekularkonjugate von bioabbaubaren polyestern und bioaktiven polypeptiden
US5395490A (en) 1993-05-14 1995-03-07 Intertec, Ltd. Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies
US6060037A (en) * 1993-10-26 2000-05-09 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US5489670A (en) * 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
DE69627153T2 (de) 1995-06-27 2003-12-04 Elan Pharmaceuticals, Inc.(N.D.Ges.D.Staates Delaware) Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
CZ157998A3 (cs) 1995-11-24 1998-12-16 Smithkline Beecham S. P. A. Chinolinové deriváty, způsob jejich přípravy, farmaceutický prostředek a použití
DE69731623D1 (de) 1996-04-23 2004-12-23 Ipsen Mfg Ireland Ltd Saure Polymilchsäure Polymere
US6589750B2 (en) 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
SI0975347T1 (sl) 1997-02-28 2008-08-31 Nycomed Gmbh Sinergistična kombinacija PDE inhibitorjev in agonistov adenilat ciklaze oziroma agonistov gvanil ciklize
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
WO1999014239A1 (fr) 1997-09-12 1999-03-25 Wolf Georg Forssmann Composition pour le traitement du diabete sucre et de l'obesite
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
IT1304152B1 (it) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
EP1593387B1 (fr) 1999-06-23 2008-11-19 Institut Pasteur Compositions pour le traitement de désordres interpersonnels et comportementaux
CZ2002333A3 (cs) 1999-08-18 2002-08-14 Societe De Conseils De Recherches Et D'application Sloučenina 1 obsahující sloučeninu A, farmaceutický prostředek a pouľití sloučeniny A pro výrobu léčiva pro léčení chorob
SE9903291D0 (sv) 1999-09-15 1999-09-15 Astra Ab New process
AU7700400A (en) 1999-10-06 2001-05-10 Pharmacia Corporation Uroguanylin as an intestinal cancer inhibiting agent
CZ299726B6 (cs) 1999-11-01 2008-11-05 Lécivo pro lécení zácpy a syndromu dráždivého tracníku
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
WO2001064212A1 (fr) 2000-03-01 2001-09-07 University College London Modulateurs de l'absorption d'endocannabinoide et des recepteurs de vallinoide
ES2235806T3 (es) 2000-12-22 2005-07-16 Institut Pasteur Procedimiento de seleccion de moleculas ligando que se unen especificamente al sitio de union nep para el prentapeptido qhnpr.
EP1365753A2 (fr) 2001-02-02 2003-12-03 Pharmacia Corporation Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin
JP4206272B2 (ja) 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト
EP1451211A2 (fr) 2001-03-30 2004-09-01 University of Copenhagen Compositions et procedes de modulation de l'activite du recepteur signalant la guanylyl cylclase et de traitement de la maladie de meniere
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
EP1392729A2 (fr) 2001-06-05 2004-03-03 Yalcin Cetin Utilisation d'un peptide qui active la guanylate-cyclase c pour le traitement de maladies des voies respiratoires par les voies aeriennes, medicament, dispositif d'inhalation et methode de diagnostic
FR2830451B1 (fr) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
EP1321142A1 (fr) 2001-12-21 2003-06-25 Novartis AG Forme solide pour l'administration orale du Tégaserode
US20040121961A1 (en) 2002-02-04 2004-06-24 Jaime Masferrer Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
US20050171014A1 (en) 2002-02-27 2005-08-04 Government Of The United States Of America, Represented By The Secretary, Department Of Health Conjugates of ligand linker and cytotoxic agent and related composition and methods of use
ES2399880T3 (es) 2002-03-15 2013-04-04 Cypress Bioscience, Inc. Milnaciprán para el tratamiento del síndrome del intestino irritable
EP1505974B1 (fr) 2002-05-17 2009-04-22 Tioga Pharmaceuticals, Inc. Utilisation de composes s'averant efficaces en tant que modulateurs selectifs des recepteurs des opiaces
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE365174T1 (de) 2003-01-28 2007-07-15 Microbia Inc Zusammensetzungen zur behandlung von gastrointestinalen störungen
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US8206704B2 (en) 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
US20090253634A1 (en) * 2005-08-19 2009-10-08 Microbia, Inc. Methods and Compositions for the Treatment of Gastrointestinal Disorders

Also Published As

Publication number Publication date
JP2006516631A (ja) 2006-07-06
DE602004007105D1 (de) 2007-08-02
CY1111058T1 (el) 2015-06-11
RU2014153593A3 (fr) 2018-08-06
WO2004069165A2 (fr) 2004-08-19
FR13C0030I1 (fr) 2013-07-05
RU2014153593A (ru) 2016-07-20
LTC1594517I2 (lt) 2020-03-10
RU2353383C2 (ru) 2009-04-27
US7704947B2 (en) 2010-04-27
CY2013021I1 (el) 2020-05-29
KR101227627B1 (ko) 2013-01-31
CN101787073A (zh) 2010-07-28
NO336768B1 (no) 2015-11-02
BRPI0407071A (pt) 2006-01-24
BR122018074353B8 (pt) 2023-05-02
IL169863A (en) 2012-10-31
FR13C0029I1 (fr) 2013-07-05
RU2005127058A (ru) 2006-03-10
BE2013C032I2 (fr) 2023-08-22
EP1594517B1 (fr) 2007-06-20
ES2285417T3 (es) 2007-11-16
NL300593I1 (nl) 2015-10-21
NO334112B1 (no) 2013-12-09
SI2246360T1 (sl) 2012-10-30
LU92201I2 (fr) 2013-11-22
ATE365174T1 (de) 2007-07-15
US20090005534A1 (en) 2009-01-01
BR122018074353B1 (pt) 2019-07-16
LU92200I2 (fr) 2024-03-21
EP1911763A2 (fr) 2008-04-16
CA2514507A1 (fr) 2004-08-19
BRPI0407071B8 (pt) 2021-05-25
SG192300A1 (en) 2013-08-30
RU2008147983A (ru) 2010-06-10
JP5563384B2 (ja) 2014-07-30
DK2246360T3 (da) 2012-08-13
HK1078768A1 (en) 2006-03-24
SI1911763T1 (sl) 2010-11-30
MXPA05008097A (es) 2006-02-08
EP1594517A2 (fr) 2005-11-16
EP2246360B1 (fr) 2012-06-27
CN100589839C (zh) 2010-02-17
CY2013021I2 (el) 2025-07-04
KR20110114682A (ko) 2011-10-19
AU2004210161B2 (en) 2009-11-26
PT1594517E (pt) 2007-07-20
IL221380A0 (en) 2012-09-24
EP2246360A1 (fr) 2010-11-03
CY1110905T1 (el) 2015-06-10
KR101227626B1 (ko) 2013-02-01
LU92200I1 (fr) 2020-06-02
NZ570134A (en) 2010-02-26
JP2013116910A (ja) 2013-06-13
ES2387848T3 (es) 2012-10-02
PT2246360E (pt) 2012-08-31
JP4584911B2 (ja) 2010-11-24
JP2010222377A (ja) 2010-10-07
JP5748791B2 (ja) 2015-07-15
NO2014013I1 (no) 2014-06-02
PT1911763E (pt) 2010-11-18
DE602004028678D1 (de) 2010-09-23
DE602004007105T2 (de) 2008-02-28
CY1113217T1 (el) 2016-04-13
ES2350123T3 (es) 2011-01-18
NL300593I2 (nl) 2020-04-15
NO2014013I2 (no) 2014-05-21
SG168407A1 (en) 2011-02-28
EP1911763B1 (fr) 2010-08-11
CN101787073B (zh) 2013-12-25
US20040266989A1 (en) 2004-12-30
NZ541595A (en) 2008-08-29
EP1594517A4 (fr) 2006-03-29
KR20050106404A (ko) 2005-11-09
CA2514507C (fr) 2012-03-20
DK1594517T3 (da) 2007-10-29
RU2543350C2 (ru) 2015-02-27
NO20130460L (no) 2005-10-26
AU2004210161A1 (en) 2004-08-19
DK1911763T3 (da) 2010-11-15
ATE477268T1 (de) 2010-08-15
NO20053864L (no) 2005-10-26
RU2763796C2 (ru) 2022-01-11
US8080526B2 (en) 2011-12-20
US20110124583A1 (en) 2011-05-26
CY2013022I1 (el) 2020-05-29
SI1594517T1 (sl) 2007-10-31
EP1911763A3 (fr) 2008-06-25
HUS1300022I1 (hu) 2019-11-28
WO2004069165A3 (fr) 2005-03-17
NO20053864D0 (no) 2005-08-18
AU2009235993A1 (en) 2009-11-26
AU2009235993B2 (en) 2013-07-04
CN1795007A (zh) 2006-06-28
BRPI0407071B1 (pt) 2019-02-12

Similar Documents

Publication Publication Date Title
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
EP1601251A4 (fr) Compos s pour le traitement de troubles m taboliques
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
EP1838320A4 (fr) Antagonistes de cxcr4 pour le traitement de troubles medicaux
EP1931691A4 (fr) Inhibiteurs d'odcase pour le traitement du paludisme
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
MA29098B1 (fr) Compositions pour le traitement du vhc
EP1534074A4 (fr) Polytherapie pour le traitement de l'obesite
EP2056848A4 (fr) Utilisation d'extraits pour le traitement de troubles viraux
FR22C1033I1 (fr) Utilisation de dihydroimidazolones pour le traitement des chiens
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
EP2307011A4 (fr) Utilisation d'isoindoles pour le traitement de troubles neurocomportementaux
EP1804787A4 (fr) Composition flavonoide pour le traitement des maladies bucco-dentaires
EP1664011A4 (fr) Compositions ophtalmiques pour le traitement de l'hypertension oculaire
EP1581243A4 (fr) Lactoferrine orale pour le traitement des sepsies
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
EP2124948A4 (fr) Compositions pour le traitement de troubles vasculaires hyperprolifératifs et de cancers
EP1773970A4 (fr) Formules de lubrifiants pour le traitement de toles
EP1750513A4 (fr) Utilisation de ligands gpcr54 pour le traitement de l'infertilite
EP1799258A4 (fr) Methodes pour un traitement d'angiogenese
EP1933813A4 (fr) Liposomes de sphingomyeline pour le traitement de troubles de vessie hyperactive
MA28493B1 (fr) Sulfonamides destinés au traitement de troubles neurodégénératifs
FR2835851B1 (fr) Composition pour le traitement d'alliages de magnesium